CatalÓ  |  Castellano

Servei de Ginecologia
Hospital Universitari Vall d'Hebron
└rea Materno-Infantil

Passeig de la Vall d'Hebron, 119-129 - 08035 Barcelona
TelŔfon: 93 489 30 00
Unitats > Patologia MamÓria > Publicacions
Patologia MamÓria

Publicacions i CapÝtols de llibres de 2010-2012:

  1. Rubio IT. Use of genome typing in breast cancer. J Surg Oncol. 2009 Jan 1;99(1):3-4
  2.  Rubio IT, Aznar F, Lirola J, Peg V, Xercavins J. Intraoperative Assessment of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy in Patients with Breast Cancer. Ann Surg Oncol. 2010 Jan;17(1):235-9.  
  3. Cebrecos I, Córdoba O, Deu J, Xercavins J, Rubio IT. Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy? Eur J Surg Oncol. 2010 Jun;36(6):528-34.
  4. Balmaña J, Diez O, Rubio I, Castiglione M; ESMO Guidelines Working Group.BRCA in breast cancer:ESMO Clinical Practice Guidelines. Ann Oncol. 2010 May;21 Suppl 5:v20-2
  5. Toscas JI, Linero D, Rubio I, Hidalgo A, Arnalte R, Escudé L, Cozzi L, Fogliata A, Miralbell R. Boosting the tumor bed from deep-seated tumors in early stage breast cáncer: a planning study between electron, photon, and proton beams. Radiother Oncol 2010; 96: 192-8
  6. Merced C, Rubio IT, Rodríguez J, Peg V, Xercavins J.Breast metástasis from rhabdomyosarcoma of the nasal septum in a pregnant adult women.Breast J. 2011 Jul-Aug;17(4):420-1
  7. Sabaté M, Roca I, Córdoba O, Kysiel N, Rubio I, Castell J. Contralateral axillary drainage in breast tumor recurrence. Rev Esp med Nucl 2011. 30(5): 327-328
  8. Espinosa-Bravo M, Sao Avilés A, Esgueva A, Córdoba O, Rodriguez J, Cortadellas T, Mendoza C, Salvador R, Xercavins J, Rubio IT. Breast conservative surgery after neoadjuvant chemotherapy in breast cáncer patients: Comparison of two tumor localization methods. Eur J Surg Oncol. 2011 Dec;37(12):1038-43
  9. Cortadellas T, Córdoba O, Espinosa-Bravo M, Mendoza-Santin C, Rodríguez-Fernández J, Esgueva A, Alvarez-Vinuesa M, Rubio IT, Xercavins J. Electrothermal bipolar vessel sealing system in axillary dissection: A prospective randomized clinical study. Int J Surg. 2011;9(8):636-40
  10. Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011 Sep;22 Suppl 6:vi31-4
  11. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. Eur J Cancer. 2011 Dec;47(18):2742-9
  12. Córdoba O, Bellet M, Vidal X, Cortés J, Llurba E, Rubio IT, Xercavins J. Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. Breast. 2012 Jun;21(3):272-5.
  13. Rubio IT, Cebrecos I, Peg V, Esgueva A, Mendoza C, Cortadellas T, Cordoba O, Espinosa-Bravo M, Xercavins J.Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer. J Surg Oncol. 2012 Jul 1;106(1):89-93
  14. Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene. 2012 May 28. [Epub ahead of print]
  15. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition. Cancer Discov. 2012 Aug 24
  16. Córdoba O, Llurba E, Saura C, Rubio I, Ferrer Q, Cortés J, Xercavins J. Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes.  Breast. 2012 Oct 29. Epub ahead of print